Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Stopped early · Phase 2

Conditions studied: Acute Myelogenous Leukemia

In brief

Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.

Key facts

Study ID

NCT01289678

Run by

Leo W. Jenkins Cancer Center

People needed

18

Starts

2006-07-01

Expected to finish

2016-08-31

Last updated by the study team

2019-09-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment
• Total WBC recovery of 500 mm3 prior to IL-2 treatment
• Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment
• Active infection controlled prior to starting IL-2 treatment
• Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment
• O2 saturation >90% prior to starting treatment
• Stable cardiopulmonary status prior to starting IL-2 treatment
• Serum creatinine < or equal to 2.0 mg/dl
• Total bilirubin and AST <3x upper limits normal

You may not qualify if…

• Acute Promyelocytic Leukemia
• Active thrombocytopenic bleeding
• Cardiac ejection fraction below 45%
• Pregnancy and/or lactation

Where it is running

• Leo W. Jenkins Cancer Center — Greenville, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.